FLAG THERAPEUTICS to Present at NYC Oncology Conference

NEW YORK -- FLAG Therapeutics Inc., headquartered in Raleigh, North Carolina, is a clinical stage oncology company with two novel classes of small molecule, water-soluble drugs: 1) anti-angiogenic & anti-tubulin (AA/AT) and 2) purine synthesis inhibitors (PSI). FLAG’s President and Chief Executive Officer (CEO) Frank Sorgi, Ph.D.,MBA, will discuss FLAG’s two platforms and its application in orphan oncology, specifically glioblastoma multiforme (GBM).

FLAG Therapeutics’ leading candidate for treating glioblastoma is the first compound ever to combine the dual-action of the two major classes of anti-cancer drugs - anti-angiogenic and anti-tubulin (AA/AT) - into a single molecule.  This dual acting compounds deliver a simultaneous anti-angiogenic and anti-tubulin assault on the tumor. By attacking the tumor when it is most vulnerable, FLAG hopes to increase drug efficacy while decreasing the potency of the anti-tubulin activity for improved tolerability.  In addition, FLAG’s anti-angiogenic and anti-tubulin compounds are designed to circumvent the two major mechanisms of drug resistance (P-glycoprotein (PGP) and β-III tubulin overexpression) that limit the utility of current therapies.

Join FLAG at the NYC Oncology Investor Conference Oct. 30 at 6 pm https://www.nyconcologyconference.com/ #oncology

Who: Frank Sorgi, Ph.D., MBA,  President and CEO of FLAG Therapeutics

What: Presentation on dual-acting, anti-angiogenic & anti-tubulin anti-cancer compounds

When: Tuesday, October 30 at 3:30 p.m. EDT

Where: Rockefeller Center, 1270 6th Avenue, New York, NY, 10020

About FLAG

FLAG Therapeutics Inc., headquartered in Raleigh, North Carolina, is an early-stage oncology company focused on the development of therapies based on two novel classes of small molecule, water-soluble drugs.  In vivo studies suggest that both classes of compounds, anti-angiogenic/anti-tubulin (AA/AT) compounds and Purine Synthesis Inhibitors, hold the potential to treat multiple cancer types with greater safety and efficacy than conventional therapies.  FLAG Therapeutics has obtained exclusive worldwide rights to these compounds from Duquesne University. To learn more about FLAG Therapeutics, please visit www.flagtherapeutics.com.  

Aaron White